-
Something wrong with this record ?
Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high risk early breast cancer: Results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes
Nadia Harbeck, Priya Rastogi, Joyce O'Shaughnessy, Fran Boyle, Javier Cortes, Hope S. Rugo, Matthew P. Goezt, Erika Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey Tryakin, Patrick Neven, Jens Huober, Rubin Wei, Valérie André, M. Munoz,...
Status not-indexed Language English Country Czech Republic
Document type Meeting Abstract
- Publication type
- Meeting Abstract MeSH
Baylor University Medical Center TexasOncology US Oncology Dallas USA
Breast Center Kantonsspital St Gallen St Gallen Switzerland
Eli Lilly and Company Indianapolis USA
Eli Lilly ČR s r o Prague Czech Republic
Hospital General Universitario Gregorio Maranon UniversidadComplutense CIBERONC GEICAM Madrid Spain
International Breast Cancer Center Quironsalud Group Barcelona Spain
Medical University of Gdansk Poland
Multidisciplinary Breast Center University Hospitals Leuven Belgium
N N Blokhin Russian Cancer Research Center Moscow Russian Federation
Sarah Cannon Research Institute Tennessee Oncology Nashville USA
Sydney Medical School University of Sydney Australia
The Royal Marsden NHS Foundation Trust London UK
UPMC Hillman Cancer Center and NSABP Foudation Pittsburgh USA
Poster
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006459
- 003
- CZ-PrNML
- 005
- 20240416101138.0
- 007
- ta
- 008
- 240415s2024 xr f 00 0|eng||
- 009
- PC
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Harbeck, Nadia $u Breast Centre, Department of Gynecology and Obstetrics, Comprehensive Cancer Centre München, LMU University Hospital, Munich, Germany
- 245 10
- $a Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high risk early breast cancer: Results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes / $c Nadia Harbeck, Priya Rastogi, Joyce O'Shaughnessy, Fran Boyle, Javier Cortes, Hope S. Rugo, Matthew P. Goezt, Erika Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Alexey Tryakin, Patrick Neven, Jens Huober, Rubin Wei, Valérie André, M. Munoz, Belen San Antonio, Ashwin Shahir, Miguel Martin, Stephen Johnston, Vladimír Habětínek
- 500 __
- $a Poster
- 590 __
- $a NEINDEXOVÁNO
- 655 _7
- $a abstrakt z konference $7 D016416 $2 czmesh
- 700 1_
- $a Rastogi, Priya $u UPMC Hillman Cancer Center and NSABP Foudation, Pittsburgh, USA
- 700 1_
- $a O'Shaughnessy, Joyce $u Baylor University Medical Center, TexasOncology, US Oncology, Dallas, USA
- 700 1_
- $a Boyle, Fran $u Sydney Medical School,University of Sydney, Australia
- 700 1_
- $a Cortes, Javier $u International Breast Cancer Center, Quironsalud Group, Barcelona, Spain
- 700 1_
- $a Rugo, Hope S. $u Department of Medicine, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
- 700 1_
- $a Goezt, Matthew P. $u Mayo Clinic, Rochester, USA
- 700 1_
- $a Hamilton, Erika $u Sarah Cannon Research Institute, Tennessee Oncology, Nashville, USA
- 700 1_
- $a Huang, Chiun-Sheng $u Department of Surgery, National Taiwan University Hospital, National Taiwan Uviversity College of Medicine, Taipei City, Taiwan
- 700 1_
- $a Senkus, Elzbieta $u Medical University of Gdansk, Poland
- 700 1_
- $a Tryakin, Alexey $u N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
- 700 1_
- $a Neven, Patrick $u Multidisciplinary Breast Center, University Hospitals Leuven, Belgium
- 700 1_
- $a Huober, Jens $u Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland
- 700 1_
- $a Wei, Rubin $u Eli Lilly and Company, Indianapolis, USA
- 700 1_
- $a André, Valérie $u Eli Lilly and Company, Indianapolis, USA
- 700 1_
- $a Munoz, M. $u Eli Lilly and Company, Indianapolis, USA
- 700 1_
- $a San Antonio, Belen $u Eli Lilly and Company, Indianapolis, USA
- 700 1_
- $a Shahir, Ashwin $u Eli Lilly and Company, Indianapolis, USA
- 700 1_
- $a Martin, Miguel $u Hospital General Universitario Gregorio Maranon, UniversidadComplutense, CIBERONC, GEICAM, Madrid, Spain
- 700 1_
- $a Johnston, Stephen $u The Royal Marsden NHS Foundation Trust, London, UK
- 700 1_
- $a Habětínek, Vladimír $u Eli Lilly ČR, s.r.o., Prague, Czech Republic
- 773 0_
- $t Prague Onco Journal. 15. pražské mezioborové onkologické kolokvium Prague ONCO, 24.-26. ledna 2024 $x 1804-2252 $z 978-80-87339-26-8 $g Roč. 2024, č. 1 (2024), s. 42-43 $w MED00177652
- 773 0_
- $t Prague Onco Journal $x 1804-2252 $z 978-80-88400-57-8 $g (2024), s. 42-43 $w MED00177652
- 910 __
- $a ABA008 $b B 2634 $c 664 $y p $z 0
- 990 __
- $a 20240410154339 $b ABA008
- 991 __
- $a 20240416102909 $b ABA008
- 999 __
- $a ok $b bmc $g 2077256 $s 1216226
- BAS __
- $a 6
- BMC __
- $a 2024 $b 2024 $c 1 $d 42-43 $z 978-80-87339-26-8 $i 1804-2252 $m Prague Onco Journal $n Prague Onco J. $o 15. pražské mezioborové onkologické kolokvium Prague ONCO, 24.-26. ledna 2024 $x MED00177652
- BMC __
- $a 2024 $d 42-43 $i 1804-2252 $m Prague Onco Journal $n Prague Onco J. $x MED00177652 $z 978-80-88400-57-8
- LZP __
- $a NLk 2024-16/dkbi